Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InspireMD (NSPR) Cash & Equivalents (2016 - 2025)

InspireMD filings provide 16 years of Cash & Equivalents readings, the most recent being $8.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 52.74% to $8.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.9 million, a 52.74% decrease, with the full-year FY2025 number at $8.9 million, down 52.74% from a year prior.
  • Cash & Equivalents hit $8.9 million in Q4 2025 for InspireMD, down from $63.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $63.4 million in Q3 2025 to a low of $3.9 million in Q3 2022.
  • Median Cash & Equivalents over the past 5 years was $11.8 million (2021), compared with a mean of $17.1 million.
  • Biggest five-year swings in Cash & Equivalents: soared 1301.91% in 2021 and later tumbled 84.57% in 2022.
  • InspireMD's Cash & Equivalents stood at $12.0 million in 2021, then plummeted by 61.41% to $4.6 million in 2022, then soared by 108.12% to $9.6 million in 2023, then skyrocketed by 96.22% to $18.9 million in 2024, then tumbled by 52.74% to $8.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $8.9 million (Q4 2025), $63.4 million (Q3 2025), and $11.5 million (Q2 2025) per Business Quant data.